Abstract
The fate of 5-aminosalicylic acid (5-ASA), which is used in the treatment of chronic inflammatory bowel diseases, was studied in six healthy volunteers receiving doses of 100 mg and 250 mg intravenous bolus as well as 250 mgper os (slow release). Following intravenous administration, the drug was rapidly eliminated with a plasma half-life of about 40 min, mainly due to rapid metabolism. No parent drug was recovered in feces, and the total recovery following oral administration (30%) was significantly lower than following the intravenous doses (77% and 72%). Nonlinear pharmacokinetics were suggested as the 2.5-fold increase in intravenous dose was followed by a significant relative increase (>2.5) in the renal elimination of 5-ASA, as well as a significant decrease (<2.5) in the elimination of the metaboliteN-acetyl-5-ASA. There was also a trend towards a decreasing total body clearance and metabolic ratio. The present study confirms earlier findings on the pharmacokinetics of 5-ASA and suggests a possible saturation of theN-acetylating system in the dose range studied. This may be of interest in the design of controlled-release formulations and dosage regimes for the treatment of diseases of the small-bowel, where 5-ASA is easily absorbed. Further, for the first time, a marked difference in the intestinal fate compared to the systemic fate of the drug is demonstrated, suggesting alternative presystemic metabolism of 5-ASA, which may bear relevance to its mode of action. Further studies on the pharmacokinetics of 5-ASA, preferably in patients, are warranted.
Similar content being viewed by others
References
Peppercorn MA: Sulfasalazine. Pharmacology, clinical use, toxicity and new drug development. Ann Intern Med 101:377–386, 1984
Campieri M, Lanfranchi GA, Bazzochi G, Brignola C, Sarti F, Franzin G, Batocchia A, Labo G, Dal Monte PR: Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 2:270–271, 1981
Danish 5-ASA Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double blind multicentre trial. Dig Dis Sci 32:598–602, 1987
Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H: 5-Aminosalicylic acid in a slow release preparation: Bioavailability, plasma levels and excretion in man. Gastroenterology 83:1062–1070, 1982
Myers B, Evans DNW, Rhodes J, Evans BK, Hughes BR, Lee MG, Richens A, Richards D: Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 28:196–200, 1987
Evans DAP, White TA: Human acetylation polymorphism. J Lab Clin Med 13:394–403, 1964
Hansen SH: Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high performance liquid chromatography on dynamically modified silica gel. J Chromatogr 226:504–509, 1981
Calder IC, Funder CC, Green CR, Ham KN, Tange JD: Comparative nephrotoxicity of aspirin and phenacetin derivates. Br Med J 4:518–521, 1971
Nelder FA, Mead R: A simplex method for function minimization. Computer J 7:308–313, 1965
Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the estimation of linear pharmacokinetic equations. J Pharmacokinet Biopharmacol 6:165–175, 1978
Gibaldi M, Perrier D: Pharmacokinetics, New York, Marcel Dekker, 1982
Nielsen OH, Bondesen S: Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 16:738–740, 1983
Fischer C, Maier K, Klotz U: Specific measurement of 5-aminosalicyl acid and its acetylated metabolite in bile. Clin Pharmacol 15:273–274, 1983
Allgayer H, Ahnfelt NO, Kruis W, Klotz U, Frank-Holmberg K, Soederberg HNA, Paumgartner G: ColonicN-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 97:38–41, 1989
Christensen LA, Slot O, Sanchez G, Boserup J, Rasmussen SN, Bondesen S, Hansen SH, Hvidberg EF: Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol 23:365–369, 1987
Houston JB, Cassidy MK: Rate-limiting steps in metabolic kinetics: Formation of 5-acetyl-aminosalicylate after administration of 5-aminosalicylate. J Pharm Pharmacol 34:536–538, 1982
Binder V, Halskov S, Hvidberg EF, Kristensen E, Riis P, Tougaard L, Willumsen L: A controlled study of 5-acetaminosalicylic acid as enema in active ulcerative colitis. Scand J Gastroenterol 16:1122, 1981
Campieri M, Lanfranchi GA, Boschi S, Brignola C, Bazzochi G, Gionchetti P, Minguzzi MR, Belluzzi, Labo G: Topical administration of 5-aminosalicylic acid in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut 26:400–504, 1985
Bondesen S, Schou JB, Pedersen V, Rafiolsadat Z, Hansen SH, Hvidberg EF: Absorption of 5-aminosalicylic acid from colon and rectum. Br J Clin Pharmacol 25:269–272, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bondesen, S., Hegnhøj, J., Larsen, F. et al. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus andper os slow-release formulation. Digest Dis Sci 36, 1735–1740 (1991). https://doi.org/10.1007/BF01296618
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01296618